Drug-drug Interaction Study (CKD-501, Ketoconazole)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

CKD-501, Ketoconazole

Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.

Trial Locations (1)

120-752

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Severance Hospital

OTHER

lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT01330563 - Drug-drug Interaction Study (CKD-501, Ketoconazole) | Biotech Hunter | Biotech Hunter